P2Y12 antagonist monotherapy

DRUG3 trials

Sponsors

Samsung Medical Center, Gangnam Severance Hospital

Conditions

Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)Coronary Artery DiseaseHigh Bleeding Risk

Phase 4

Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR

Not yet recruitingNCT06763744

Samsung Medical CenterAcute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk

Start: 2025-06-01End: 2029-12-31Target: 3000Updated: 2025-05-18

Unknown Phase

Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES

Samsung Medical CenterCoronary Artery Disease

Start: 2014-03-18End: 2020-07-07Updated: 2019-01-31

Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent

CompletedNCT03447379

Gangnam Severance HospitalCoronary Artery Disease

Start: 2017-12-15End: 2022-08-17Updated: 2025-03-12

Related Papers

P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent

JAMA Network Open2024-03-0716 citations

The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention

Korean Circulation Journal2024-01-011 citations

Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention.

2023-11-205 citations

Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention

JAMA Cardiology2022-09-2813 citations

Clopidogrel monotherapy in patients with and without on-treatment high platelet reactivity: a SMART-CHOICE substudy

EuroIntervention2021-12-019 citations

P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor

Heart2021-03-237 citations

Safety of 3‐Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus‐Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART‐CHOICE Trial

Journal of the American Heart Association2020-12-218 citations

Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention

JAMA2019-06-25587 citations